目的:评估含0.01g/L硫柳汞非单剂量自体血清(AutologousSeYum,AS)滴眼治疗重度干眼的有效性和安全性。方法:接受至少12wk传统干眼治疗无效的重度干眼患者13例26眼,采用自身对照方法,用20%含0.01g/L硫柳汞非单剂量的AS滴眼8wk后,再用50%相同制剂AS滴眼8wk。滴眼后2,4,8,12,16wk分别比较基础泪河高度、泪膜破裂时问、角膜荧光染色、基础泪液分泌试验、角膜知觉、自觉症状评分。结果:滴眼后2wk,基础泪河高度、患者自觉症状与用药前比较差异有统计学意义(P〈0.01和P〈0.05);滴眼后4wk,泪膜破裂时间、角膜荧光素染色与用药前比较差异有统计学意义(P〈0.05);滴眼后8wk,基础泪液分泌、角膜知觉与用药前比较差异有统计学意义(P〈0.01和P〈0.05)。滴眼观察期间未发现明显并发症。结论:含0.01g/L硫柳汞非单剂量AS滴眼能安全有效地缓解重度干眼患者的症状和体征。
AIM: To evaluate the efficacy and safety of autologous serum(AS) eye drops with 0. 01g/L Thiomersal in the treatment of recalcitrant dry eye syndrome. METHODS: Twentysix eyes of 13 patients with recalcitrant dry eye syndrome were enrolled in this self- control study, and treated with 2 months of AS 20% with 0.01g/L Thiomersal followed by 2 months of AS 50% with 0.01g/L Thiomersal. Tear membrane lever (TML), tear film break-up time (BUT), corneal fluorescein staining (FL), Schirmer [ test with topical anaesthesia(S [ t), corneal sensitivity test and subjective symptom scoring were performed at entry, 2, 4, 8, 12 and 16 weeks. Statistical analysis was carried out using Wilcoxon's signed rank test. RESULTS: Both TML and subjective symptom scorning showed significant improvement after 2 weeks of treatment ( P〈0.01, P〈0.05) ; after 4 weeks of treatment, BUT and FL were significant improvement(P〈0.05) ; S [ t and corneal sensitivity were significant increased after 8 weeks of treatment ( P〈 0. 01, P〈 0. 05). No significant complications were reported in this study. CONCLUSION: AS eye drops 20% with 0. 01g/L Thiomersal are effective and safe in treating refractory dry eye syndrome, and should be available as an alternative management option in developing countries.